Overview

Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars

Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
0
Participant gender:
All
Summary
Background: Scars widen when the overlying musculature pulls apart suture lines. Because Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces temporary muscle paralysis, the purpose of this current study is to evaluate the beneficial effects of Botulinum toxin type A (BTA) on scar formation. Aim of this study: The aim of this study is to evaluate the efficacy and safety of early postoperative Botulinum Toxin type A (BTA) injection on improving vertical or oblique facial surgical scars. Materials and methods: Patients with vertical or oblique forehead lacerations, treated by primary closure, will be enrolled in this study and randomized into two groups: One group (n =6) will receive BTA injection within 5 days of primary closure and the other group (n = 6) will receive no further treatment. Vancouver scar scale (VSS) Scores and wound width will be determined at the 1, 3 and 6 months follow-up visits, along with clinical photographs. Results: Data will be collected, tabulated and statically analyzed. Key words: Botulinum Toxin Type A; facial scarring; wound healing; scar maturation
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Alexandria University
Treatments:
abobotulinumtoxinA
Botulinum Toxins, Type A
Criteria
Inclusion Criteria:

- • Patients aged from 18 to 40 years.

- Patients free from any systemic disease.

- Patients who understand verbal and written instructions

Exclusion Criteria:

- • Patients with horizontal forehead lacerations.

- Patients suffering from complicated forehead lacerations that require grafting.

- Patients with forehead burns.

- Patients with neuromuscular disorders.

- Patients with previous surgical or non-surgical intervention.

- Patients allergic to drugs used in this study